Remission and relapse of diabetes after sleeve gastrectomy and one‐anastomosis gastric bypass: The Tehran Obesity Treatment Study

Aims To evaluate the rates and predictors of remission and relapse of type 2 diabetes mellitus (T2DM) in individuals with T2DM undergoing sleeve gastrectomy (SG) or one‐anastomosis gastric bypass (OAGB). Methods An observational prospective study with 5 years of follow‐up was conducted in a total of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diabetes, obesity & metabolism obesity & metabolism, 2024-12, Vol.26 (12), p.6007-6015
Hauptverfasser: Sadeghi, Sara, Hosseinpanah, Farhad, Khalaj, Alireza, Ebadinejad, Amir, Mahdavi, Maryam, Valizadeh, Majid, Barzin, Maryam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6015
container_issue 12
container_start_page 6007
container_title Diabetes, obesity & metabolism
container_volume 26
creator Sadeghi, Sara
Hosseinpanah, Farhad
Khalaj, Alireza
Ebadinejad, Amir
Mahdavi, Maryam
Valizadeh, Majid
Barzin, Maryam
description Aims To evaluate the rates and predictors of remission and relapse of type 2 diabetes mellitus (T2DM) in individuals with T2DM undergoing sleeve gastrectomy (SG) or one‐anastomosis gastric bypass (OAGB). Methods An observational prospective study with 5 years of follow‐up was conducted in a total of 891 patients (82.5% female) with concomitant T2DM and obesity (body mass index ≥ 30.0 kg/m2) undergoing SG or OAGB between March 2013 and March 2021. T2DM remission was defined as achieving a glycated haemoglobin (HbA1c) level 
doi_str_mv 10.1111/dom.15974
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3111202744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3111202744</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2434-1a33d2cbff3d4b06aa8507a6e6553995544d187f09ca20de6ec1d34f705abdc33</originalsourceid><addsrcrecordid>eNp10Utu1TAUBmALUdFSGLABZIkJDNL6lRcz1BZaqehKcBlHJ_YJTZXEFx8HlBkSG2CNrARz0zJAIh7Esj7_sv0z9kyKE5m-U-fHE5nXpXnAjqQpdCa1Kh7u5yqraqEO2WOiWyGE0VX5iB3qWhtTmfyI_fiAY0_U-4nD5HjAAXaE3Hfc9dBiROLQRQycBsSvyD8DxYA2-nHZb_AT_vr-E6a07EdPPa2it7xddkD0mm9vkG_xJsDENy1SHxe-DQhxxCnyj3F2yxN20MFA-PTuf8w-vb3Ynl1m15t3V2dvrjOrjDaZBK2dsm3XaWdaUQBUuSihwCLPdV3nuTFOVmUnagtKOCzQSqdNV4ocWme1PmYv19xd8F9mpNikq1scBpjQz9To9JZKqNKYRF_8Q2_9HKZ0uqSULgqRRlKvVmWDJwrYNbvQjxCWRormTzNNaqbZN5Ps87vEuR3R_ZX3VSRwuoJv_YDL_5Oa8837NfI3gG-aXA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3123660606</pqid></control><display><type>article</type><title>Remission and relapse of diabetes after sleeve gastrectomy and one‐anastomosis gastric bypass: The Tehran Obesity Treatment Study</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Sadeghi, Sara ; Hosseinpanah, Farhad ; Khalaj, Alireza ; Ebadinejad, Amir ; Mahdavi, Maryam ; Valizadeh, Majid ; Barzin, Maryam</creator><creatorcontrib>Sadeghi, Sara ; Hosseinpanah, Farhad ; Khalaj, Alireza ; Ebadinejad, Amir ; Mahdavi, Maryam ; Valizadeh, Majid ; Barzin, Maryam</creatorcontrib><description>Aims To evaluate the rates and predictors of remission and relapse of type 2 diabetes mellitus (T2DM) in individuals with T2DM undergoing sleeve gastrectomy (SG) or one‐anastomosis gastric bypass (OAGB). Methods An observational prospective study with 5 years of follow‐up was conducted in a total of 891 patients (82.5% female) with concomitant T2DM and obesity (body mass index ≥ 30.0 kg/m2) undergoing SG or OAGB between March 2013 and March 2021. T2DM remission was defined as achieving a glycated haemoglobin (HbA1c) level &lt; 48 mmol/mol and a fasting plasma glucose (FPG) level &lt;7 mmol/L, and being off glucose‐lowering agents/insulin. T2DM relapse was defined as when FPG or HbA1c reverted to the diabetic range (≥7 mmol/L and ≥48 mmol/mol, respectively), or there was a need for pharmacotherapy. Results After bariatric surgery, the overall T2DM remission and relapse rates were 61.4 per 1000 person‐months (95% confidence interval [CI] 56.8–66.4) and 5.7 per 1000 person‐months (95% CI 4.1–7.9), respectively. These rates were similar in the SG and OAGB groups. Multivariate hazard ratio analysis identified history of insulin therapy and T2DM duration prior to surgery as predictors of remission, while treatment with ≥2 glucose‐lowering agents was the only relapse predictor. Additionally, patients undergoing SG experienced either remission or relapse within a significantly shorter time frame compared to those undergoing OAGB. Conclusion After 5 years of follow‐up, there were no significant differences between the SG and OAGB groups with regard to T2DM remission and relapse. Bariatric surgery was less likely to result in remission in patients with a history of insulin therapy and longer durations of T2DM prior to surgery. Furthermore, patients who received ≥2 glucose‐lowering agents, despite possible remission, were at a higher risk of experiencing late relapse.</description><identifier>ISSN: 1462-8902</identifier><identifier>ISSN: 1463-1326</identifier><identifier>EISSN: 1463-1326</identifier><identifier>DOI: 10.1111/dom.15974</identifier><identifier>PMID: 39344845</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Anastomosis ; Blood Glucose - analysis ; Blood Glucose - metabolism ; Body mass index ; Diabetes ; diabetes mellitus ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - surgery ; Drug therapy ; Female ; Follow-Up Studies ; Gastrectomy ; Gastrectomy - methods ; Gastric bypass ; Gastric Bypass - methods ; Gastrointestinal surgery ; Glucose ; Glycated Hemoglobin - analysis ; Glycated Hemoglobin - metabolism ; Hemoglobin ; Humans ; Insulin ; Iran - epidemiology ; Male ; Middle Aged ; Obesity ; Obesity - complications ; Obesity - surgery ; Obesity, Morbid - complications ; Obesity, Morbid - surgery ; one‐anastomosis gastric bypass ; Patients ; Prospective Studies ; Recurrence ; relapse ; Remission ; Remission Induction ; sleeve gastrectomy ; Surgery ; Treatment Outcome</subject><ispartof>Diabetes, obesity &amp; metabolism, 2024-12, Vol.26 (12), p.6007-6015</ispartof><rights>2024 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2434-1a33d2cbff3d4b06aa8507a6e6553995544d187f09ca20de6ec1d34f705abdc33</cites><orcidid>0000-0001-7718-1952 ; 0000-0002-3405-6681 ; 0000-0002-3147-6103</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fdom.15974$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.15974$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39344845$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sadeghi, Sara</creatorcontrib><creatorcontrib>Hosseinpanah, Farhad</creatorcontrib><creatorcontrib>Khalaj, Alireza</creatorcontrib><creatorcontrib>Ebadinejad, Amir</creatorcontrib><creatorcontrib>Mahdavi, Maryam</creatorcontrib><creatorcontrib>Valizadeh, Majid</creatorcontrib><creatorcontrib>Barzin, Maryam</creatorcontrib><title>Remission and relapse of diabetes after sleeve gastrectomy and one‐anastomosis gastric bypass: The Tehran Obesity Treatment Study</title><title>Diabetes, obesity &amp; metabolism</title><addtitle>Diabetes Obes Metab</addtitle><description>Aims To evaluate the rates and predictors of remission and relapse of type 2 diabetes mellitus (T2DM) in individuals with T2DM undergoing sleeve gastrectomy (SG) or one‐anastomosis gastric bypass (OAGB). Methods An observational prospective study with 5 years of follow‐up was conducted in a total of 891 patients (82.5% female) with concomitant T2DM and obesity (body mass index ≥ 30.0 kg/m2) undergoing SG or OAGB between March 2013 and March 2021. T2DM remission was defined as achieving a glycated haemoglobin (HbA1c) level &lt; 48 mmol/mol and a fasting plasma glucose (FPG) level &lt;7 mmol/L, and being off glucose‐lowering agents/insulin. T2DM relapse was defined as when FPG or HbA1c reverted to the diabetic range (≥7 mmol/L and ≥48 mmol/mol, respectively), or there was a need for pharmacotherapy. Results After bariatric surgery, the overall T2DM remission and relapse rates were 61.4 per 1000 person‐months (95% confidence interval [CI] 56.8–66.4) and 5.7 per 1000 person‐months (95% CI 4.1–7.9), respectively. These rates were similar in the SG and OAGB groups. Multivariate hazard ratio analysis identified history of insulin therapy and T2DM duration prior to surgery as predictors of remission, while treatment with ≥2 glucose‐lowering agents was the only relapse predictor. Additionally, patients undergoing SG experienced either remission or relapse within a significantly shorter time frame compared to those undergoing OAGB. Conclusion After 5 years of follow‐up, there were no significant differences between the SG and OAGB groups with regard to T2DM remission and relapse. Bariatric surgery was less likely to result in remission in patients with a history of insulin therapy and longer durations of T2DM prior to surgery. Furthermore, patients who received ≥2 glucose‐lowering agents, despite possible remission, were at a higher risk of experiencing late relapse.</description><subject>Adult</subject><subject>Anastomosis</subject><subject>Blood Glucose - analysis</subject><subject>Blood Glucose - metabolism</subject><subject>Body mass index</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - surgery</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastrectomy</subject><subject>Gastrectomy - methods</subject><subject>Gastric bypass</subject><subject>Gastric Bypass - methods</subject><subject>Gastrointestinal surgery</subject><subject>Glucose</subject><subject>Glycated Hemoglobin - analysis</subject><subject>Glycated Hemoglobin - metabolism</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Insulin</subject><subject>Iran - epidemiology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - complications</subject><subject>Obesity - surgery</subject><subject>Obesity, Morbid - complications</subject><subject>Obesity, Morbid - surgery</subject><subject>one‐anastomosis gastric bypass</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>relapse</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>sleeve gastrectomy</subject><subject>Surgery</subject><subject>Treatment Outcome</subject><issn>1462-8902</issn><issn>1463-1326</issn><issn>1463-1326</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10Utu1TAUBmALUdFSGLABZIkJDNL6lRcz1BZaqehKcBlHJ_YJTZXEFx8HlBkSG2CNrARz0zJAIh7Esj7_sv0z9kyKE5m-U-fHE5nXpXnAjqQpdCa1Kh7u5yqraqEO2WOiWyGE0VX5iB3qWhtTmfyI_fiAY0_U-4nD5HjAAXaE3Hfc9dBiROLQRQycBsSvyD8DxYA2-nHZb_AT_vr-E6a07EdPPa2it7xddkD0mm9vkG_xJsDENy1SHxe-DQhxxCnyj3F2yxN20MFA-PTuf8w-vb3Ynl1m15t3V2dvrjOrjDaZBK2dsm3XaWdaUQBUuSihwCLPdV3nuTFOVmUnagtKOCzQSqdNV4ocWme1PmYv19xd8F9mpNikq1scBpjQz9To9JZKqNKYRF_8Q2_9HKZ0uqSULgqRRlKvVmWDJwrYNbvQjxCWRormTzNNaqbZN5Ps87vEuR3R_ZX3VSRwuoJv_YDL_5Oa8837NfI3gG-aXA</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Sadeghi, Sara</creator><creator>Hosseinpanah, Farhad</creator><creator>Khalaj, Alireza</creator><creator>Ebadinejad, Amir</creator><creator>Mahdavi, Maryam</creator><creator>Valizadeh, Majid</creator><creator>Barzin, Maryam</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7718-1952</orcidid><orcidid>https://orcid.org/0000-0002-3405-6681</orcidid><orcidid>https://orcid.org/0000-0002-3147-6103</orcidid></search><sort><creationdate>202412</creationdate><title>Remission and relapse of diabetes after sleeve gastrectomy and one‐anastomosis gastric bypass: The Tehran Obesity Treatment Study</title><author>Sadeghi, Sara ; Hosseinpanah, Farhad ; Khalaj, Alireza ; Ebadinejad, Amir ; Mahdavi, Maryam ; Valizadeh, Majid ; Barzin, Maryam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2434-1a33d2cbff3d4b06aa8507a6e6553995544d187f09ca20de6ec1d34f705abdc33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Anastomosis</topic><topic>Blood Glucose - analysis</topic><topic>Blood Glucose - metabolism</topic><topic>Body mass index</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - surgery</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastrectomy</topic><topic>Gastrectomy - methods</topic><topic>Gastric bypass</topic><topic>Gastric Bypass - methods</topic><topic>Gastrointestinal surgery</topic><topic>Glucose</topic><topic>Glycated Hemoglobin - analysis</topic><topic>Glycated Hemoglobin - metabolism</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Insulin</topic><topic>Iran - epidemiology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - complications</topic><topic>Obesity - surgery</topic><topic>Obesity, Morbid - complications</topic><topic>Obesity, Morbid - surgery</topic><topic>one‐anastomosis gastric bypass</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>relapse</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>sleeve gastrectomy</topic><topic>Surgery</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sadeghi, Sara</creatorcontrib><creatorcontrib>Hosseinpanah, Farhad</creatorcontrib><creatorcontrib>Khalaj, Alireza</creatorcontrib><creatorcontrib>Ebadinejad, Amir</creatorcontrib><creatorcontrib>Mahdavi, Maryam</creatorcontrib><creatorcontrib>Valizadeh, Majid</creatorcontrib><creatorcontrib>Barzin, Maryam</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes, obesity &amp; metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sadeghi, Sara</au><au>Hosseinpanah, Farhad</au><au>Khalaj, Alireza</au><au>Ebadinejad, Amir</au><au>Mahdavi, Maryam</au><au>Valizadeh, Majid</au><au>Barzin, Maryam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Remission and relapse of diabetes after sleeve gastrectomy and one‐anastomosis gastric bypass: The Tehran Obesity Treatment Study</atitle><jtitle>Diabetes, obesity &amp; metabolism</jtitle><addtitle>Diabetes Obes Metab</addtitle><date>2024-12</date><risdate>2024</risdate><volume>26</volume><issue>12</issue><spage>6007</spage><epage>6015</epage><pages>6007-6015</pages><issn>1462-8902</issn><issn>1463-1326</issn><eissn>1463-1326</eissn><abstract>Aims To evaluate the rates and predictors of remission and relapse of type 2 diabetes mellitus (T2DM) in individuals with T2DM undergoing sleeve gastrectomy (SG) or one‐anastomosis gastric bypass (OAGB). Methods An observational prospective study with 5 years of follow‐up was conducted in a total of 891 patients (82.5% female) with concomitant T2DM and obesity (body mass index ≥ 30.0 kg/m2) undergoing SG or OAGB between March 2013 and March 2021. T2DM remission was defined as achieving a glycated haemoglobin (HbA1c) level &lt; 48 mmol/mol and a fasting plasma glucose (FPG) level &lt;7 mmol/L, and being off glucose‐lowering agents/insulin. T2DM relapse was defined as when FPG or HbA1c reverted to the diabetic range (≥7 mmol/L and ≥48 mmol/mol, respectively), or there was a need for pharmacotherapy. Results After bariatric surgery, the overall T2DM remission and relapse rates were 61.4 per 1000 person‐months (95% confidence interval [CI] 56.8–66.4) and 5.7 per 1000 person‐months (95% CI 4.1–7.9), respectively. These rates were similar in the SG and OAGB groups. Multivariate hazard ratio analysis identified history of insulin therapy and T2DM duration prior to surgery as predictors of remission, while treatment with ≥2 glucose‐lowering agents was the only relapse predictor. Additionally, patients undergoing SG experienced either remission or relapse within a significantly shorter time frame compared to those undergoing OAGB. Conclusion After 5 years of follow‐up, there were no significant differences between the SG and OAGB groups with regard to T2DM remission and relapse. Bariatric surgery was less likely to result in remission in patients with a history of insulin therapy and longer durations of T2DM prior to surgery. Furthermore, patients who received ≥2 glucose‐lowering agents, despite possible remission, were at a higher risk of experiencing late relapse.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>39344845</pmid><doi>10.1111/dom.15974</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7718-1952</orcidid><orcidid>https://orcid.org/0000-0002-3405-6681</orcidid><orcidid>https://orcid.org/0000-0002-3147-6103</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1462-8902
ispartof Diabetes, obesity & metabolism, 2024-12, Vol.26 (12), p.6007-6015
issn 1462-8902
1463-1326
1463-1326
language eng
recordid cdi_proquest_miscellaneous_3111202744
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Adult
Anastomosis
Blood Glucose - analysis
Blood Glucose - metabolism
Body mass index
Diabetes
diabetes mellitus
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - surgery
Drug therapy
Female
Follow-Up Studies
Gastrectomy
Gastrectomy - methods
Gastric bypass
Gastric Bypass - methods
Gastrointestinal surgery
Glucose
Glycated Hemoglobin - analysis
Glycated Hemoglobin - metabolism
Hemoglobin
Humans
Insulin
Iran - epidemiology
Male
Middle Aged
Obesity
Obesity - complications
Obesity - surgery
Obesity, Morbid - complications
Obesity, Morbid - surgery
one‐anastomosis gastric bypass
Patients
Prospective Studies
Recurrence
relapse
Remission
Remission Induction
sleeve gastrectomy
Surgery
Treatment Outcome
title Remission and relapse of diabetes after sleeve gastrectomy and one‐anastomosis gastric bypass: The Tehran Obesity Treatment Study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T00%3A58%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Remission%20and%20relapse%20of%20diabetes%20after%20sleeve%20gastrectomy%20and%20one%E2%80%90anastomosis%20gastric%20bypass:%20The%20Tehran%20Obesity%20Treatment%20Study&rft.jtitle=Diabetes,%20obesity%20&%20metabolism&rft.au=Sadeghi,%20Sara&rft.date=2024-12&rft.volume=26&rft.issue=12&rft.spage=6007&rft.epage=6015&rft.pages=6007-6015&rft.issn=1462-8902&rft.eissn=1463-1326&rft_id=info:doi/10.1111/dom.15974&rft_dat=%3Cproquest_cross%3E3111202744%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3123660606&rft_id=info:pmid/39344845&rfr_iscdi=true